Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Hepatitis B Virus

Hepatitis B Virus

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hepatitis B Virus

6 trials tracked for Hepatitis B Virus: 1 in phase 3 or 4.

6Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 1 Phase 2 1 Phase 1 3 Other / NA 1
  1. Phase 3 Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB Completed
  2. Phase 2 Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials Completed
  3. Phase 1 A Double-Blind Single-Ascending Dose (SAD) and Multiple-Ascending Dose (MAD) Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7049389 in Healthy Chinese Participants Completed
  4. Phase 1 Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment Completed
  5. Phase 1 A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting Completed
  6. N/A Interventions to Increase HBV Vaccinations in Sexually Transmitted Disease (STD) Clinics Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
JAK inhibitors are associated with higher hepatitis B virus reactivation rates than IL-12/23 or IL-17 inhibitors
Gastroenterology Meta-analysis
JAK inhibitors are associated with higher hepatitis B virus reactivation rates than IL-12/23 or IL-17 inhibitors Specific Immune Inhibitors Show Varying Risks for Hepatitis B Reactivation
This meta-analysis of 29 studies evaluated the risk of hepatitis B virus reactivation (HBVr) in patients receiving various immunomodulators.…
New analysis shows that certain immune inhibitors like JAK inhibitors may carry a higher risk of hepatitis B reactivation than other drug cl…
Jul 1, 2026